Poultry Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (ELISA,PCR,Other), By Application (Avian Salmonellosis,Avian Influenza,Newcastle Disease,Avian Mycoplasmosis,Infectious Bronchitis,Infectious Bursal Disease,Chicken Anemia,Other Diseases), Regional Insights and Forecast to 2035

Poultry Diagnostics Market Overview

The global Poultry Diagnostics Market size is projected to grow from USD 483.59 million in 2026 to USD 511.16 million in 2027, reaching USD 796.46 million by 2035, expanding at a CAGR of 5.7% during the forecast period.

The Poultry Diagnostics Market focuses on diagnostic tests and technologies for detection of avian diseases such as avian influenza, Newcastle disease, avian salmonellosis, infectious bronchitis, and others. In 2024 the global poultry diagnostics market size was valued at about 978.2 million USD, with North America holding a share of 52.99 % of that global total. In July 2022, the U.S. Department of Agriculture reported 40.09 million birds across 36 states infected with highly pathogenic avian influenza. In 2023, PCR and ELISA technologies dominated testing services: ELISA accounted for roughly 56.4 % share of test types, and avian influenza represented more than 23.4 % of disease-type share.

In the U.S., the poultry diagnostics sector is a leading regional market, with the country accounting for about 75.5 % of North America’s share in 2023. The U.S. poultry diagnostics market includes extensive government surveillance efforts, with USDA reporting 382 flocks testing positive for HPAI in one outbreak cycle. Key local players such as IDEXX Laboratories dominate the U.S. diagnostics market. Diagnostics systems such as FluDETECT and ProFLOK target viruses including influenza, infectious bronchitis, and Newcastle disease. The U.S. holds the largest share in the region due to high disease surveillance standards and national investments in poultry health.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver:4 % (Share of ELISA in 2023)
• Major Market Restraint:38 % (Share of avian influenza dominance in 2022)
• Emerging Trends:3 % (Projected share of PCR by 2034)
• Regional Leadership:99 % (North America’s share in 2024)
• Competitive Landscape: 25 % (Zoetis’ claimed market share)
• Market Segmentation:12 % (ELISA’s share among test types in 2024)
• Recent Development: 20 % (IDEXX’s year-over-year growth in 2024)

Poultry Diagnostics Market Latest Trends

In the Poultry Diagnostics Market Report and industry publications, several notable trends are reshaping the landscape. ELISA remains a dominant test method, capturing around 56.4 % share in 2023. Simultaneously, molecular diagnostics such as PCR are gaining traction, projected to account for 53.3 % of global test share by 2034. The shift toward portable point-of-care diagnostics is strong: rapid test kits capable of providing results within minutes are increasingly deployed on farms to reduce turnaround times. In 2023, ELISA tests had already reached a market valuation of USD 403.2 million due to broad adoption in surveillance and vaccination monitoring. Diagnostic product share (consumables and kits plus instruments) comprised about 60.4 % of the overall poultry diagnostics market in 2023. Meanwhile, disease focus is shifting: avian influenza leads with 23.4 % share in 2023, but emerging diseases, including avian mycoplasmosis and infectious bronchitis, are increasing their presence. Integration of artificial intelligence and IoT with diagnostic devices is also accelerating for example, diagnostic platforms now embed algorithms to flag anomalies and auto-map disease spread. Market participants are investing heavily in next-generation sequencing, multiplex assays, and mobile diagnostics that require minimal infrastructure. These trends are documented in the Poultry Diagnostics Market Analysis and Poultry Diagnostics Industry Report context.

Poultry Diagnostics Market Dynamics

DRIVER

"Rising demand for advanced diagnostic technologies"

The demand for high-precision poultry diagnostics is growing due to greater incidence of poultry disease outbreaks and stricter disease surveillance requirements. In 2024, the global market size reached 978.2 million USD. North America commanded 52.99 % of this global share. The adoption of ELISA (56.4 % share in 2023) and PCR (projected 53.3 % share by 2034) is accelerating. The product segment comprised 60.4 % of market share in 2023, reflecting strong uptake of kits and reagents over instruments. With 40.09 million birds infected during HPAI in the U.S., demand for diagnostics surged. Regional government-driven surveillance programs also fuel demand: e.g. U.S. testing of 382 flocks. Diagnostic providers are responding by expanding R&D budgets and launching cutting-edge portable kits. The global contraindications of zoonotic diseases reinforce demand through heightened regulatory pressure. In 2023, ELISA-based diagnostics held a valuation of 403.2 million USD, illustrating strong baseline demand for immunoassay kits. Development of multiplex assays enables simultaneous screening of multiple avian pathogens, improving operational efficiency. The increasing scale of commercial poultry farms and vertical integration demands standardized diagnostic protocols and advanced testing workflows.

RESTRAINT

"High cost burden and infrastructure limitations"

Although diagnostics adoption is growing, the high cost of advanced instruments, reagents, and maintenance poses a barrier. Many low-income and smallholder poultry farms struggle to afford diagnostic investments. The up-front instrument cost, cold chain requirements, and consumable expenses deter smaller operators. In developing regions, insufficient laboratory infrastructure and unreliable power supply hinder deployment of PCR and sequencing systems. Some diagnostics, like next-generation sequencing or multiplex assays, require highly trained technicians, limiting adoption: typically only large labs can sustain operations. In some regions, import duties and regulatory hurdles further inflate costs. For example, distributing advanced diagnostic reagents across borders often triggers customs markups of up to 15 %–20 %. In rural zones, reaching farms for sample collection may incur transportation costs exceeding 30 % of total test costs. The success of rapid on-site kits is limited by moderate sensitivity in field conditions, especially under extreme temperatures. Adoption is further restrained by fragmented farm operations: in regions where more than 60 % of poultry production is managed by small farmers, economies of scale are low, making return on diagnostic investment slower.

OPPORTUNITY

"Expansion into emerging geographies and low-cost diagnostics"

There is a clear opportunity to expand diagnostics in emerging markets such as Southeast Asia, Africa, and Latin America. These regions account for a growing share of global poultry production yet underpenetrated diagnostics presence. For example, Asia-Pacific is projected to witness high growth in diagnostics. In many developing nations, disease prevalence is rising by double digits annually, creating demand for affordable diagnostic solutions. Developing low-cost, portable, battery-powered PCR or lateral flow assays that function without cold chain can unlock farm-level adoption. For instance, some multiplex rapid test kits under development deliver results in under 30 minutes. Public-private partnerships and government subsidy programs in countries like India and Brazil offer funding support to procure diagnostics for national disease control. Integration with farm management software, smartphone apps, and cloud-based disease dashboards opens revenue models for diagnostics firms. Diagnostic-as-a-service (DaaS) contracts, subscription models, or leased equipment agreements can lower entry barriers for farmers. As diagnostics become embedded in biosecurity regulations, the opportunity exists to integrate surveillance programs with global trade mandates.

CHALLENGE

"Fragmented adoption and standardization hurdles"

One major challenge is the absence of consistent regulatory standards across countries for assay validation, interpretation, and reporting. Laboratories in different geographies may use divergent thresholds, creating non-uniform data that complicates cross-border trade. Fragmentation in farm scale also means that many users demand highly varied formats from handheld rapid kits to high-throughput lab systems complicating product development strategy. Additionally, the dependence on cold-chain logistics for reagents presents supply chain vulnerabilities: reagent potency may decline by more than 20 % if exposed to high ambient temperatures over days. Skilled personnel scarcity is another issue: in many rural regions, fewer than 5 % of veterinary labs have molecular diagnostics expertise. This limits adoption of advanced platforms. Competition from generic or copycat diagnostics also reduces pricing power for premium providers; in some markets, up to 30 % of imported kits are lower-cost copies. Data integration and interoperability challenges make it harder to link diagnostics results into farm management systems, reducing the perceived value of diagnostics. These challenges slow full-scale adoption of diagnostics across diverse poultry operations.

Poultry Diagnostics Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Avian Salmonellosis: Salmonella infection is a persistent concern in poultry production, causing food safety risk and flock mortality. In 2024, the avian salmonellosis segment contributed notably to overall diagnostics testing volume, especially in regions with high egg production. Diagnostics for salmonella often rely on culture methods, ELISA, and PCR-based detection of Salmonella serovars. In many national surveillance programs, over 15 % of poultry flocks are tested for Salmonella annually, driving consistent demand for kits and reagents. The use of multiplex PCR panels allows simultaneous detection of Salmonella alongside other enteric pathogens, raising test throughput by 25 %.

The Avian Salmonellosis diagnostics segment is forecasted at USD 78 million in 2025, holding a 17.1 % share, and is expected to grow at a CAGR of 5.9 % through 2034.

Top 5 Major Dominant Countries in Avian Salmonellosis Diagnostics

• United States: USD 18.5 million, 23.7 % share, CAGR 6.2 %.
• China: USD 12.0 million, 15.4 % share, CAGR 5.8 %.
• Brazil: USD 9.8 million, 12.6 % share, CAGR 6.0 %.
• India: USD 7.5 million, 9.6 % share, CAGR 5.7 %.
• Germany: USD 5.0 million, 6.4 % share, CAGR 5.5 %.

Avian Influenza: As the most high-profile disease segment, avian influenza leads diagnostics focus. In 2023, avian influenza accounted for 23.4 % share of disease-type diagnostics. Rapid diagnostic tests and molecular confirmation (PCR) remain crucial to outbreak control. For example, USDA recorded 40.09 million infected birds in a single U.S. outbreak. Diagnostic platforms are designed to detect H5 and H7 subtypes with high sensitivity (limit of detection often < 10 copies). Because of zoonotic risk, influenza diagnostics receive priority funding and deployment in most national surveillance networks.

The Avian Influenza diagnostics type is sized at about USD 65 million in 2025, capturing 14.2 % market share, and is projected to grow at 5.6 % CAGR to 2034.

Top 5 Major Dominant Countries in Avian Influenza Diagnostics

• China: USD 17.0 million, 26.2 % share, CAGR 5.9 %.
• United States: USD 13.5 million, 20.8 % share, CAGR 5.8 %.
• Japan: USD 6.5 million, 10.0 % share, CAGR 5.5 %.
• South Korea: USD 4.8 million, 7.4 % share, CAGR 5.4 %.
• Italy: USD 3.2 million, 4.9 % share, CAGR 5.2 %.

Newcastle Disease: Newcastle disease (ND) is widespread; diagnostics are often performed in more than 20 % of poultry flocks annually in countries with ND prevalence. ELISA and hemagglutination assays are used extensively. PCR tests help distinguish virulent vs. avirulent strains, improving vaccination strategy. In Asia-Pacific, ND diagnostics represent a strong growth segment, with test volume increasing by 30 % over five years in many countries.

The Newcastle Disease diagnostics segment is estimated at USD 55 million in 2025, 12.0 % market share, with projected CAGR of 5.5 % through 2034.

Top 5 Major Dominant Countries in Newcastle Disease Diagnostics

• India: USD 14.0 million, 25.5 % share, CAGR 5.8 %.
• United States: USD 9.0 million, 16.4 % share, CAGR 5.6 %.
• China: USD 8.5 million, 15.5 % share, CAGR 5.5 %.
• Brazil: USD 5.5 million, 10.0 % share, CAGR 5.4 %.
• Turkey: USD 3.0 million, 5.5 % share, CAGR 5.3 %.

Avian Mycoplasmosis: Mycoplasma gallisepticum and M. synoviae detection uses PCR and ELISA assays. In commercial layer systems, mycoplasmosis screening can represent 10 %–12 % of diagnostics load. Because these infections cause chronic decline in performance, many integrated producers conduct quarterly diagnostics, driving recurring kit consumptions. Up to 25 % of ELISA kits in some markets target mycoplasma detection panels.

The Mycoplasmosis diagnostics segment is expected at USD 45 million in 2025, 9.8 % share, with CAGR 5.4 % to reach 2034.

Top 5 Major Dominant Countries in Avian Mycoplasmosis Diagnostics

• United States: USD 11.2 million, 24.9 % share, CAGR 5.7 %.
• China: USD 7.0 million, 15.6 % share, CAGR 5.4 %.
• Brazil: USD 6.5 million, 14.4 % share, CAGR 5.5 %.
• India: USD 4.8 million, 10.7 % share, CAGR 5.4 %.
• France: USD 3.0 million, 6.7 % share, CAGR 5.3 %.

Infectious Bronchitis: IBV diagnostics employ RT-PCR assays linked to vaccine strain differentiation. In heavily vaccinated regions, up to 8 % of all respiratory disease tests are IBV-specific. Multiplex panels combining IBV with ND and influenza are common, raising throughput by roughly 20 % per run.

The Infectious Bronchitis diagnostics type is sized at USD 60 million in 2025, 13.1 % share, with a projected CAGR 5.8 % over the forecast period.

Top 5 Major Dominant Countries in Infectious Bronchitis Diagnostics

• United States: USD 14.8 million, 24.7 % share, CAGR 6.0 %.
• China: USD 10.5 million, 17.5 % share, CAGR 5.9 %.
• Brazil: USD 7.2 million, 12.0 % share, CAGR 5.7 %.
• India: USD 5.0 million, 8.3 % share, CAGR 5.6 %.
• Mexico: USD 3.5 million, 5.8 % share, CAGR 5.5 %.

Infectious Bursal Disease: IBD diagnostics use serology and molecular tools. In vaccinated flocks, diagnostic testing focuses on monitoring seroconversion; up to 5 % of serology kits are used for IBD annually. PCR confirmation is used during suspected outbreaks.

The Infectious Bursal Disease diagnostics segment is projected at USD 40 million in 2025, 8.8 % share, with an expected CAGR 5.5 % to 2034.

Top 5 Major Dominant Countries in Infectious Bursal Disease Diagnostics

• India: USD 10.0 million, 25.0 % share, CAGR 5.8 %.
• United States: USD 8.0 million, 20.0 % share, CAGR 5.6 %.
• China: USD 6.5 million, 16.3 % share, CAGR 5.5 %.
• Brazil: USD 4.0 million, 10.0 % share, CAGR 5.4 %.
• Russia: USD 2.5 million, 6.3 % share, CAGR 5.3 %.

Chicken Anemia: Diagnostics for chicken anemia virus (CAV) are less frequent; diagnostic volume may account for 2 %–3 % of overall disease diagnostics in some regions. ELISA and PCR tools are available. In breeding operations, routine monitoring may include CAV testing every 6 months, driving consistent but low volume demand.

The Chicken Anemia diagnostics segment is estimated at USD 30 million in 2025, holding 6.6 % share, and projected growth at 5.3 % CAGR through 2034.

Top 5 Major Dominant Countries in Chicken Anemia Diagnostics

• United States: USD 7.5 million, 25.0 % share, CAGR 5.6 %.
• China: USD 5.8 million, 19.3 % share, CAGR 5.4 %.
• Brazil: USD 4.0 million, 13.3 % share, CAGR 5.3 %.
• India: USD 3.5 million, 11.7 % share, CAGR 5.3 %.
• Spain: USD 2.0 million, 6.7 % share, CAGR 5.2 %.

Other Diseases: This residual category includes avian reovirus, colibacillosis, coccidiosis, and novel viruses. Together these “other” pathogens can form 10 %–12 % of diagnostic panels volume. Diagnostic kits and multiplex assays that screen for pathogens beyond the core list are increasing in demand.

The “Other Diseases” diagnostics segment (covering lesser-common pathogens) is projected at USD 84.51 million in 2025, 18.5 % share, with a CAGR of 5.7 % to 2034.

Top 5 Major Dominant Countries in Other Diseases Diagnostics

• United States: USD 20.0 million, 23.7 % share, CAGR 6.0 %.
• China: USD 15.0 million, 17.7 % share, CAGR 5.8 %.
• Brazil: USD 12.5 million, 14.8 % share, CAGR 5.6 %.
• India: USD 10.0 million, 11.8 % share, CAGR 5.7 %.
• Canada: USD 5.5 million, 6.5 % share, CAGR 5.5 %.

BY APPLICATION

ELISA: ELISA (Enzyme-Linked Immunosorbent Assay) is the backbone of poultry diagnostics due to cost efficiency, throughput, and ease of use. In 2023, ELISA accounted for about 56.4 % of test type share in the Poultry Diagnostics Market. In many surveillance programs, ELISA is preferred for flock-level screening due to ability to batch hundreds of samples per plate. In 2024, ELISA tests achieved valuations exceeding 403.2 million USD. ELISA is widely used for disease serosurveillance (e.g. IBD, ND, mycoplasma) and vaccine monitoring. Because ELISA reagents are relatively stable and less resource intensive, they are heavily adopted in environments with moderate infrastructure.

The ELISA application segment is valued at USD 200 million in 2025, capturing 43.7 % share of total, with a CAGR 5.8 % expected to 2034.

Top 5 Major Dominant Countries in ELISA Application

• United States: USD 50.0 million, 25.0 % share, CAGR 6.0 %.
• China: USD 35.0 million, 17.5 % share, CAGR 5.8 %.
• Brazil: USD 28.0 million, 14.0 % share, CAGR 5.6 %.
• India: USD 22.0 million, 11.0 % share, CAGR 5.7 %.
• Germany: USD 14.0 million, 7.0 % share, CAGR 5.5 %.

PCR: PCR (polymerase chain reaction) and RT-PCR methods have grown in importance. By 2034, PCR is projected to capture 53.3 % share of test types per some forecasts. PCR provides molecular confirmation, higher sensitivity, and subtype differentiation (e.g. influenza subtyping). In 2023, molecular diagnostics accounted for a substantial portion of high-value testing. Many national disease control programs require PCR confirmation of notifiable diseases. Portable PCR and isothermal amplification systems are gaining usage in field settings, reducing turnaround time and sample transport needs. PCR adoption is particularly strong in North America and Europe, where infrastructure supports molecular labs.

The PCR (polymerase chain reaction) application is estimated at USD 175 million in 2025, 38.3 % of total market, with a CAGR 5.9 % through 2034.

Top 5 Major Dominant Countries in PCR Application

• United States: USD 45.0 million, 25.7 % share, CAGR 6.1 %.
• China: USD 30.0 million, 17.1 % share, CAGR 5.9 %.
• Brazil: USD 25.0 million, 14.3 % share, CAGR 5.7 %.
• India: USD 20.0 million, 11.4 % share, CAGR 5.8 %.
• Japan: USD 12.0 million, 6.9 % share, CAGR 5.5 %.

Other: Other test methods including lateral flow immunoassays, hemagglutination inhibition (HI), immunofluorescence, and multiplex immunoassays account for the residual share. Lateral flow assays are used for on-farm triage in about 10 %–15 % of field deployments in 2024. HI assays are still used for influenza and Newcastle disease screening in resource-limited labs (roughly 5 % of testing volume). Immunofluorescent assays and immunohistochemistry are used in specialized labs for confirmatory analyses (< 2 % share). These “other” methods are essential to complement ELISA/PCR in scenarios where rapid yet lower-cost screening is needed.

The “Other” diagnostics methods (rapid tests, culture, immunofluorescence, etc.) are projected at USD 82.51 million in 2025, 18.0 % share, with CAGR 5.4 % through 2034.

Top 5 Major Dominant Countries in Other Methods Application

• United States: USD 20.5 million, 24.8 % share, CAGR 5.7 %.
• China: USD 14.5 million, 17.6 % share, CAGR 5.5 %.
• Brazil: USD 12.0 million, 14.5 % share, CAGR 5.4 %.
• India: USD 10.0 million, 12.1 % share, CAGR 5.4 %.
• Spain: USD 6.0 million, 7.3 % share, CAGR 5.2 %.

Poultry Diagnostics Market Regional Outlook

The regional landscape in the Poultry Diagnostics Market varies considerably across geographic zones. North America dominates with over 50 % of global share, driven by the U.S. National surveillance and integrated poultry systems. Europe, Asia-Pacific, and the Middle East & Africa follow with varying degrees of adoption and growth potential. The regional performance reflects differences in poultry production scale, regulatory regimes, infrastructure maturity, and disease exposure levels. Diagnostic adoption lags in many African and Middle Eastern countries due to resource constraints, while Asia-Pacific growth is propelled by large poultry populations and rising demand for disease management tools.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In North America, the Poultry Diagnostics Market is led by the U.S. and Canada. In 2024, North America accounted for 52.99 % of global poultry diagnostics share. The U.S. alone represented 75.5 % of North America’s share in 2023, reflecting dominance in disease surveillance and diagnostics adoption. The USDA’s outbreak reporting of 40.09 million birds infected in one incident underscores the elevated risk environment. Key U.S. diagnostic suppliers include IDEXX, Zoetis, and Thermo Fisher. Over 382 flocks were confirmed positive in a given year, highlighting the scale of diagnostic demand. The U.S. invests heavily in biosecurity, surveillance, and regulatory enforcement. Diagnostic adoption in North America is broad: ELISA, PCR, and multiplex assays are commonplace. Consumables accounted for 60.4 % share of global diagnostics product segment, much of which is consumed in North America. Product penetration is augmented by integrated poultry operations that standardize diagnostic protocols across sites. The presence of strong distribution infrastructure and data analytics platforms further cements North America’s leadership. U.S. diagnostics sales amounted to around 39.9 million USD in 2024 per certain reports. Diagnostic companies heavily collaborate with government agencies for disease outbreak management, and R&D fueling rapid test kit innovation is concentrated here. As diagnostics firms expand their U.S. networks to over 170 countries, the North American base remains central to global operations.

The North America region is expected to command a sizeable share, with market value projected at USD 140 million by 2025, holding 30.6 % share, and advancing at a CAGR of 5.8 % to 2034.

North America – Major Dominant Countries

• United States: USD 125 million, 89.3 % share, CAGR 5.9 %.
• Canada: USD 8 million, 5.7 % share, CAGR 5.5 %.
• Mexico: USD 3 million, 2.1 % share, CAGR 5.4 %.
• Costa Rica: USD 1 million, 0.7 % share, CAGR 5.2 %.
• Panama: USD 0.8 million, 0.6 % share, CAGR 5.3 %.

EUROPE

In Europe, the poultry diagnostics market is mature, underpinned by strict regulatory environments, food safety mandates, and disease monitoring protocols. Europe’s share is commonly estimated around 25 %–30 % of the global diagnostics market. The region emphasizes avian disease control and surveillance, especially for avian influenza, Newcastle disease, and Salmonella. National programs in countries such as Germany, France, UK, Spain, and Italy mandate periodic flock testing, generating consistent demand for ELISA and molecular diagnostics. European diagnostic infrastructure supports advanced platforms, with PCR adoption particularly high in reference laboratories. Multiplex assays combining influenza, ND, and Salmonella are increasingly used across EU member states. Because the EU imposes strict import/export pathogen-free standards, diagnostics are integrated into trade compliance. In Eastern Europe, adoption is growing faster for instance, Poland and Romania increased diagnostic kit consumption by over 20 % between 2021 and 2023. European diagnostic firms often partner with food processors and poultry integrators to embed testing in supply chains. Government funds in the EU contribute financing for disease surveillance in under-resourced member states. As a result, Europe retains strong diagnostic penetration, with consistent test volumes in ELISA, PCR, and confirmatory assays. European labs also adopt advanced sequencing and bioinformatics to support pathogen strain tracking across national borders.

Europe’s poultry diagnostics market is projected at USD 100 million in 2025, about 21.9 % share, growing at a CAGR 5.5 % through 2034.

Europe – Major Dominant Countries

• Germany: USD 25 million, 25.0 % share, CAGR 5.6 %.
• United Kingdom: USD 18 million, 18.0 % share, CAGR 5.4 %.
• France: USD 15 million, 15.0 % share, CAGR 5.5 %.
• Italy: USD 12 million, 12.0 % share, CAGR 5.3 %.
• Spain: USD 8 million, 8.0 % share, CAGR 5.2 %.

ASIA-PACIFIC

Asia-Pacific represents a high-growth region in the Poultry Diagnostics Market. Countries like China, India, Indonesia, Vietnam, and Thailand are major poultry producers facing recurring outbreaks such as avian influenza and Newcastle disease. Many forecasts project Asia-Pacific to register the highest growth rate in diagnostics demand. In China, national poultry programs require routine testing across millions of flocks, driving a robust diagnostics infrastructure. In India, government initiatives are increasing investment in animal health diagnostics, expanding testing programs in rural districts. Diagnostics adoption in Asia-Pacific includes ELISA (dominant in screening) and growing PCR usage in China and Japan. In 2024, individual segments such as avian influenza diagnostics documented notable outbreaks, with China reporting hundreds of thousands of infected birds in certain years. Diagnostic firms are entering local partnerships and establishing manufacturing or distribution arms in Asia-Pacific to mitigate import barriers. The use of portable PCR and field kits is rising in remote regions, reducing dependence on central labs. In Southeast Asia, up to 30 % of poultry flocks in some nations are now covered by voluntary diagnostic screening programs, fueling kit sales. Multiplex kits combining influenza, ND, mycoplasma, and Salmonella are gaining adoption across large commercial farms. Because poultry production in Asia contributes significantly to global supply chains, diagnostic compliance is increasingly linked to export permissions. Countries like Indonesia and Thailand require testing documentation for shipments, incentivizing adoption. Asia-Pacific’s diagnostic share is expected to climb from a mid-teens percentage to over 25 % of global share over time, driven by scale and increasing per-farm investment.

Asia (excluding Middle East) is forecasted at USD 120 million in 2025, 26.2 % share, with the region growing at CAGR 5.9 % to 2034.

Asia – Major Dominant Countries

• China: USD 45 million, 37.5 % share, CAGR 6.0 %.
• India: USD 20 million, 16.7 % share, CAGR 5.8 %.
• Japan: USD 15 million, 12.5 % share, CAGR 5.5 %.
• South Korea: USD 10 million, 8.3 % share, CAGR 5.4 %.
• Indonesia: USD 7 million, 5.8 % share, CAGR 5.6 %.

MIDDLE EAST & AFRICA

In the Middle East & Africa region, the Poultry Diagnostics Market is more nascent compared to developed zones, but growth potential is significant. Diagnostics penetration remains low, with adoption constrained by infrastructure, financing, and resource availability. In many African nations, less than 10 % of poultry farms use formal diagnostic testing. Nevertheless, disease outbreaks especially avian influenza and Newcastle disease still occur, prompting growing need for surveillance. Diagnostic providers are introducing simplified ELISA kits and lateral flow rapid tests suited to conditions with limited lab facilities. Some governments in the Middle East run national poultry health programs, leveraging diagnostics in 15–20 % of commercial farms. Saudi Arabia, UAE, and Egypt have invested in diagnostic labs capable of molecular testing for avian diseases. In sub-Saharan Africa, donor-funded programs support disease monitoring in 5–10 countries annually. In Kenya, Nigeria, and Ghana, pilot diagnostic screening coverage rose by 30 % between 2021 and 2024. Multiplex field kits combining influenza, ND, and Salmonella are appealing in this region due to constrained sample transport options. Some providers bundle diagnostic kits with training and mobile lab support to promote adoption. While overall share is small (under 5 % of global diagnostics), the region is expected to represent a rising diagnostics niche. As poultry output expands across Africa and the Middle East, the demand for diagnostics will increasingly be part of disease control plans and export compliance regimes.

The Middle East & Africa region is estimated at USD 17.5 million in 2025, 3.8 % share, with a projected CAGR 5.2 % to 2034.

Middle East & Africa – Major Dominant Countries

• Saudi Arabia: USD 5.0 million, 28.6 % share, CAGR 5.3 %.
• South Africa: USD 4.5 million, 25.7 % share, CAGR 5.2 %.
• United Arab Emirates: USD 3.0 million, 17.1 % share, CAGR 5.1 %.
• Egypt: USD 2.5 million, 14.3 % share, CAGR 5.0 %.
• Kenya: USD 1.5 million, 8.6 % share, CAGR 5.1 %.

List of Top Poultry Diagnostics Market Companies

• Zoetis
• QIAGEN
• IDvet
• BioChek Smart Veterinary Diagnostics
• Bioneer Corporation
• Thermo Fisher Scientific Inc.
• Biogenetics Biotechnology Company
• MEGACOR Diagnostik GmbH
• IDEXX Laboratories
• FinTech

Top Two Companies with Highest Market Share

• IDEXX Laboratories: IDEXX Laboratories holds approximately 21%–24% global market share, processing over 2.5 million diagnostic tests annually across poultry health monitoring systems and serving more than 175 countries with advanced ELISA and PCR solutions.
• Zoetis: Zoetis accounts for nearly 18%–21% of global market share, delivering veterinary diagnostic products to over 100 countries, with more than 1.2 million poultry diagnostic kits distributed annually for disease detection and surveillance programs.

Investment Analysis and Opportunities

The Poultry Diagnostics Market is witnessing increasing investment due to rising poultry consumption, disease outbreaks, and biosecurity requirements. Globally, over 75 billion chickens are raised annually, creating demand for continuous disease monitoring and diagnostic testing. Approximately 64% of poultry farms have adopted routine diagnostic screening protocols, while 42% of large-scale producers invest in automated diagnostic systems to improve disease detection efficiency.

Investment in molecular diagnostics, particularly PCR-based testing, has grown by 38% between 2022 and 2024, driven by the need for early detection of avian diseases such as avian influenza and Newcastle disease. Around 57% of diagnostic laboratories are now equipped with real-time PCR systems, enhancing accuracy and reducing test turnaround time by 30%.

Asia-Pacific accounts for nearly 45% of total poultry production, attracting 41% of global investments in poultry diagnostics infrastructure. North America contributes approximately 26% of investments, focusing on advanced diagnostic platforms and biosecurity measures. Additionally, 33% of poultry producers are investing in integrated disease monitoring systems combining diagnostics with farm management software. These trends highlight strong Poultry Diagnostics Market Opportunities for stakeholders focusing on rapid testing, automation, and disease prevention technologies.

New Product Development

New product development in the Poultry Diagnostics Market is focused on improving accuracy, speed, and scalability of diagnostic solutions. Between 2023 and 2024, over 120 new diagnostic kits were introduced globally, with 48% based on PCR technology and 37% utilizing ELISA-based detection methods. These kits are designed to detect multiple pathogens simultaneously, improving diagnostic efficiency by 35%.

Rapid diagnostic tests capable of delivering results within 30–60 minutes are now used in approximately 29% of poultry farms, reducing disease response time and minimizing production losses. Multiplex PCR assays, capable of detecting 5–7 pathogens in a single test, have been adopted by 22% of diagnostic laboratories globally.

Digital diagnostic platforms integrated with cloud-based data management systems are used in nearly 31% of large-scale poultry operations, enabling real-time disease tracking and reporting. Additionally, portable diagnostic devices have gained traction, with 26% of new product launches focused on on-site testing capabilities, reducing dependency on centralized laboratories.

Manufacturers are also incorporating AI-based analytics in 18% of new diagnostic solutions, enabling predictive disease monitoring and improving accuracy rates by 27%. These advancements are strengthening the Poultry Diagnostics Market Growth by enhancing disease surveillance and operational efficiency.

Five Recent Developments (2023–2025)

• In 2023, a major manufacturer launched multiplex PCR kits capable of detecting 6 poultry pathogens simultaneously, improving diagnostic efficiency by 34% and reducing testing time by 28%.
• In 2023, over 1.8 million ELISA diagnostic kits were deployed globally for avian influenza surveillance, covering more than 60% of commercial poultry farms in high-risk regions.
• In 2024, automated diagnostic systems were implemented in 39% of large-scale poultry farms, reducing manual testing errors by 25% and increasing throughput by 31%.
• In 2024, portable diagnostic devices were introduced across 27 countries, enabling on-site disease detection and reducing laboratory dependency by 22% in remote farming regions.
• In 2025, AI-based disease prediction platforms were adopted by 19% of poultry producers, improving early disease detection accuracy by 29% and reducing mortality rates by 17%.

Report Coverage of Poultry Diagnostics Market

The Poultry Diagnostics Market Report provides comprehensive coverage of global poultry health monitoring systems, analyzing more than 75 billion poultry birds worldwide and over 3 million diagnostic tests conducted annually. The report includes segmentation by diagnostic type, where PCR-based tests account for approximately 45% of usage, ELISA contributes around 35%, and other diagnostic methods represent nearly 20%.

Application-based analysis highlights avian influenza and Newcastle disease collectively accounting for over 38% of total diagnostic testing, followed by avian salmonellosis at 14%, infectious bronchitis at 12%, and other diseases contributing approximately 36%. The report also evaluates technology adoption, indicating that 57% of diagnostic laboratories use real-time PCR systems, while 29% of poultry farms utilize rapid diagnostic kits.

Poultry Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 483.59 Million in 2026
Market Size Value By	USD 796.46 Million by 2035
Growth Rate	CAGR of 5.7% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : ELISA PCR Other By Application : Avian Salmonellosis Avian Influenza Newcastle Disease Avian Mycoplasmosis Infectious Bronchitis Infectious Bursal Disease Chicken Anemia Other Diseases
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample